Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ombrabulin plus paclitaxel + carboplatin vs placebo in platinum-sensitive recurrent ovarian cancer
2010-024631-16Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Ombrabulin arm with Placebo arm (2 arms). Primary endpoint: Progression-Free Survival. Started Feb 2011; status: completed.
02
Drugs
Ombrabulin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2010-024631-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024631-16.